Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Forward PE Ratio : 17.70 (As of Apr. 28, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Forward PE Ratio?

Clinuvel Pharmaceuticals's Forward PE Ratio for today is 17.70.

Clinuvel Pharmaceuticals's PE Ratio without NRI for today is 25.43.

Clinuvel Pharmaceuticals's PE Ratio for today is 25.43.

Clinuvel Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Forward PE Ratio Chart

Clinuvel Pharmaceuticals Annual Data

Trend

2023-12

2024-04

Forward PE Ratio

21.01

18.35

Clinuvel Pharmaceuticals Semi-Annual Data
	2023-12	2024-03
Forward PE Ratio	21.01	16.31

Competitive Comparison of Clinuvel Pharmaceuticals's Forward PE Ratio

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Forward PE Ratio falls into.

Clinuvel Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Clinuvel Pharmaceuticals (OTCPK:CLVLF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Clinuvel Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.